重组人粒细胞－巨噬细胞集落刺激因子治疗肺癌化疗或放疗所致的白细胞减少

对肺癌化疗、放疗后白细胞低于３．０×１０９／Ｌ者用ｒｈＧＭ－ＣＳＦ治疗９人１７次，１０例用其他升白细胞药物者作平行对照临床试验、结果表明：ｒｈ　ＧＭ－ＣＳＦ对肺癌化、放疗所致的白细胞（粒细胞）减少的疗效显著而迅速，总有效率达１００％，用药组使白细胞恢复至正常的中位数时间比对照组缩短约１０ｄ，且有良好的可耐受性、是肿瘤化疗、放疗的有力辅助药物＊Ｐ＜０．０１。下降水平与用药组均具可比性。（３）ｒｈＧＭ－ＣＳＦ：１５０μｇ／支与３００μｇ／支。方法（１）用法：化疗或放疗后外周血白细胞总数≤３．０×１０９／Ｌ时，应用ｒｈＧＭ－ＣＳＦ３００μｇ／ｄｓｃ３－７６或１５０μｇ／ｄｓｃ７－１３ｄ。本组剂量范围１．９－５．９μｇ／ｋｇ，ｑｄ。（２）疗效判断标准：用药后外周血白细胞总数升至４．０×１０９／Ｌ以上者为有效。疗效分级为：用药≤５ｄ白细胞总数升至正常水平者为显效：用药６－１０ｄ白细胞总数升至正常水平者为有效；用＞１０ｄ而白细胞计数未升高者为无效。（３）统计方法：均数的ｔ检验。结果疗效按放疗标准判断，显效１２例次（７１％），有效５例次（２９％），总有效率为１００％。用ｒｈＧＭ－ＣＳＦ前后白细胞总数的平均值分别为（２．６?

Therapeutic effect of recombinant human granulocyte-macrophage colony-stimulating factor in treating leukopenia caused by chemotherapy or radiotherapy of lung cancer

In a controlled clinical trial involving 19 patients whose WBC counts were lower than 3.0×109/L after lung cancer chemotherapy or radiotherapy,9 patients were given recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) for 17 times while other 10 patients were given conventional drugs served as control.The outcome showed rhGM-CSF had obvious and rapid effect on improving the WBC level of the patients,and its total effective rate was 100%. The tolerability of rhGM-CSF group was generally satisfied.The mean time of recruiting WBC level in rhGM-CSF group was shorter by 10 days compared with that in control.The use of rhGM-CSF in cancer drug therapy or radiotherapy was proved to be superior to that of conventional drugs.